| 67 |
Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2013, 37(4): 411-419.
|
| 68 |
Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis[J]. Liver Transpl, 2012, 18(1): 62-69.
|
| 69 |
Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial[J]. Transplantation, 2016, 100(1): 116-125.
|
| 70 |
Jeng LB, Lee SG, Soin AS, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study[J]. Am J Transplant, 2018, 18(6): 1435-1446.
|
| 71 |
Rodríguez-Perálvarez M, Guerrero M, Barrera L, et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation[J]. Transplantation, 2018, 102(12): 2056-2064.
|
| 72 |
Lin HS, Wan RH, Gao LH, et al. Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma: a systematic review and a meta-analysis[J]. Hepatobiliary Pancreat Dis Int, 2015, 14(3): 236-245.
|
| 73 |
Zhang Q, Chen H, Li Q, et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study[J]. Invest New Drugs, 2011, 29(6): 1360-1369.
|
| 74 |
Söderdahl G, Bäckman L, Isoniemi H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma[J]. Transpl Int, 2006, 19(4): 288-294.
|
| 75 |
Fujiki M, Aucejo F, Kim R. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this？[J]. Clin Transplant, 2013, 27(2): 169-177.
|
| 76 |
Shetty K, Dash C, Laurin J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma[J]. J Transplant, 2014: 913634.
|
| 77 |
Teng CL, Hwang WL, Chen YJ, et al. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study[J]. World J Surg Oncol, 2012, 10: 41.
|
| 78 |
Siegel AB, El-Khoueiry AB, Finn RS, et al. Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma[J]. Liver Cancer, 2015, 4(2): 115-125.
|
| 79 |
Satapathy SK, Das K, Kocak M, et al. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant[J]. Clin Transplant, 2018, 32(5): e13246.
|
| 80 |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
|
| 81 |
Han B, Ding H, Zhao S, et al. Potential role of adjuvant lenvatinib in improving disease-free survival for patients with high-risk hepatitis B virus-related hepatocellular carcinoma following liver transplantation: a retrospective, case control study[J]. Front Oncol, 2020, 10: 562103.
|
| 82 |
Jin X, Zhang K, Fang T, et al. Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: case report and literature review[J]. Front Oncol, 2022, 12: 951303.
|
| 83 |
Kumar V, Shinagare AB, Rennke HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature[J]. Oncologist, 2020, 25(6): 505-514.
|
| 84 |
Fisher J, Zeitouni N, Fan W, et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review[J]. J Am Acad Dermatol, 2020, 82(6): 1490-1500.
|
| 85 |
De Bruyn P, Van Gestel D, Ost P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go？[J]. Curr Opin Oncol, 2019, 31(2): 54-64.
|
| 86 |
孙景奇，杨喆，刘见鹏，等. 6例免疫检查点抑制剂挽救性治疗肝癌肝移植术后肿瘤复发的初步评价[J]. 中华器官移植杂志，2022，43(7) : 396-399.
|
| 87 |
European Association for the Study of the Liver, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
|
| 88 |
中国医师协会器官移植医师分会，中华医学会器官移植学分会肝移植学组. 中国肝癌肝移植临床实践指南(2021版)[J/CD]. 中华移植杂志：电子版，2021, 15(6): 321-328.
|
| 89 |
Muthiah MD, Tan EY, Chua SHM, et al. Nucleoside analog monotherapy for prophylaxis in Hepatitis B liver transplant patients is safe and efficacious[J]. Hepatol Int, 2020, 14(1): 57-69.
|
| 90 |
Sheng LP, Zhang JC, Zhong ZQ, et al. High-potency nucleos(t)ide analogues alone or plus immunoglobulin for HBV prophylaxis after liver transplantation: a meta-analysis[J]. Hepatol Int, 2023.[online ahead of print]
|
| 91 |
Wong TC, Fung JY, Cui TY, et al. Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis[J]. J Hepatol, 2019, 70(6): 1114-1122.
|
| 92 |
Yang JD, Aqel BA, Pungpapong S, et al. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma[J]. J Hepatol, 2016, 65(4): 859-860.
|
| 93 |
ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts[J]. J Hepatol, 2016, 65(4): 734-740.
|
| 94 |
Huang AC, Mehta N, Dodge JL, et al. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout[J]. Hepatology, 2018, 68(2): 449-461.
|
| 1 |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| 2 |
Kardashian A, Florman SS, Haydel B, et al. Liver transplantation outcomes in a U．S. multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond Milan criteria[J]. Hepatology, 2020, 72(6): 2014-2028.
|
| 3 |
Bodzin AS, Lunsford KE, Markovic D, et al. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics[J]. Ann Surg, 2017, 266(1): 118-125.
|
| 4 |
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699.
|
| 5 |
Sugawara Y, Hibi T. Surgical treatment of hepatocellular carcinoma[J]. Biosci Trends, 2021, 15(3): 138-141.
|
| 6 |
Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival[J]. Hepatology, 2001, 33(6): 1394-1403.
|
| 7 |
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J]. Lancet Oncol, 2009, 10(1): 35-43.
|
| 8 |
Busuttil RW. Liver transplantation for hepatocellular carcinoma: the Hangzhou experience[J]. Hepatobiliary Pancreat Dis Int, 2008, 7(3): 235-236.
|
| 9 |
Chen J, Xu X, Wu J, et al. The stratifying value of Hangzhou criteria in liver transplantation for hepatocellular carcinoma[J]. PLoS One, 2014, 9(3): e93128.
|
| 10 |
Orci LA, Berney T, Majno PE, et al. Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation[J]. Br J Surg, 2015, 102(10): 1250-1257.
|
| 11 |
Cheng SJ, Pratt DS, Freeman RB Jr, et al. Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis[J]. Transplantation, 2001, 72(5): 861-868.
|
| 12 |
Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan[J]. Ann Surg, 2004, 240(3): 451-459; discussion 459-461.
|
| 13 |
Akamatsu N, Kokudo N. Liver transplantation for hepatocellular carcinoma from living-donor vs. deceased donor[J]. Hepatobiliary Surg Nutr, 2016, 5(5): 422-428.
|
| 14 |
Bhangui P, Vibert E, Majno P, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation[J]. Hepatology, 2011, 53(5): 1570-1579.
|
| 15 |
Li CX, Ling CC, Shao Y, et al. CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation[J]. J Hepatol, 2016, 65(5): 944-952.
|
| 16 |
Man K, Shih KC, Ng KT, et al. Molecular signature linked to acute phase injury and tumor invasiveness in small-for-size liver grafts[J]. Ann Surg, 2010, 251(6): 1154- 1161.
|
| 17 |
Shi JH, Huitfeldt HS, Suo ZH, et al. Growth of hepatocellular carcinoma in the regenerating liver[J]. Liver Transpl, 2011, 17(7): 866-874.
|
| 18 |
Man K, Fan ST, Lo CM, et al. Graft injury in relation to graft size in right lobe live donor liver transplantation: a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression[J]. Ann Surg, 2003, 237(2): 256-264.
|
| 19 |
Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217.
|
| 20 |
Sandow T, Pavlus J, Field D, et al. Bridging hepatocellular carcinoma to transplant: transarterial chemoembolization response, tumor biology, and recurrence after transplantation in a 12-year transplant cohort[J]. J Vasc Interv Radiol, 2019, 30(7): 995-1003.
|
| 21 |
Affonso BB, Galastri FL, da Motta Leal Filho JM, et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging[J]. World J Gastroenterol, 2019, 25(37): 5687-5701.
|
| 22 |
Lee MW, Raman SS, Asvadi NH, et al. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: a 10-year intention-to-treat analysis[J]. Hepatology, 2017, 65(6): 1979-1990.
|
| 23 |
Crocetti L, de Baére T, Pereira PL, et al. CIRSE standards of practice on thermal ablation of liver tumours[J]. Cardiovasc Intervent Radiol, 2020, 43(7): 951-962.
|
| 24 |
Crocetti L, Scalise P, Bozzi E, et al. Microwave ablation of very-early- and early-stage HCC: efficacy evaluation by correlation with histology after liver transplantation[J]. Cancers, 2021, 13(14): 3420.
|
| 25 |
Gabr A, Kulik L, Mouli S, et al. Liver transplantation following Yttrium-90 radioembolization: 15-year experience in 207-patient cohort[J]. Hepatology, 2021, 73(3): 998-1010.
|
| 26 |
Zori AG, Ismael MN, Limaye AR, et al. Locoregional therapy protocols with and without radioembolization for hepatocellular carcinoma as bridge to liver transplantation[J]. Am J Clin Oncol, 2020, 43(5): 325-333.
|
| 27 |
Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis[J]. J Hepatol, 2017, 67(1): 92-99.
|
| 28 |
Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy[J]. Gastroenterology, 2004, 127(5 Suppl 1): S261-S267.
|
| 29 |
Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: to expand (beyond Milan) or downstage (to Milan)？[J]. Liver Transpl, 2018, 24(3): 327- 329.
|
| 30 |
Mehta N, Dodge JL, Goel A, et al. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy[J]. Liver Transpl, 2013, 19(12): 1343-1353.
|
| 31 |
Tsochatzis E, Garcovich M, Marelli L, et al. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma[J]. Liver Int, 2013, 33(6): 944-949.
|
| 32 |
Oligane HC, Xing M, Kim HS. Effect of bridging local-regional therapy on recurrence of hepatocellular carcinoma and survival after orthotopic liver transplantation[J]. Radiology, 2017, 282(3): 869-879.
|
| 33 |
DiNorcia J, Florman SS, Haydel B, et al. Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US Multicenter HCC Transplant Consortium[J]. Ann Surg, 2020, 271(4): 616-624.
|
| 34 |
Ravaioli M, Grazi G L, Ercolani G, et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation[J]. Transplantation, 2004, 78(12): 1780-1786.
|
| 35 |
Agopian VG, Harlander-Locke MP, Ruiz RM, et al. Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation: analysis of 3601 patients from the US Multicenter HCC Transplant Consortium[J]. Ann Surg, 2017, 266(3): 525-535.
|
| 36 |
Bharat A, Brown DB, Crippin JS, et al. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival[J]. J Am Coll Surg, 2006, 203(4): 411-420.
|
| 37 |
Kim JM, Kwon CH, Joh JW, et al. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria[J]. Transplant Proc, 2012, 44(2): 403-408.
|
| 38 |
European Association for the Study of the Liver, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
|
| 39 |
Tabrizian P, Holzner ML, Mehta N, et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma[J]. JAMA Surg, 2022, 157(9): 779-788.
|
| 40 |
Zhan QF, Ling SB, Deng YN, et al. Hangzhou criteria as downstaging criteria in hepatocellular carcinoma before liver transplantation: a multicenter study from China[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(4): 349-357.
|
| 41 |
Borentain P, Gregoire E, Louis G, et al. Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy[J]. Liver Int, 2016, 36(9): 1393.
|
| 42 |
Schwacha-Eipper B, Minciuna I, Banz V, et al. Immunotherapy as a downstaging therapy for liver transplantation[J]. Hepatology, 2020, 72(4): 1488-1490.
|
| 43 |
Qiao ZY, Zhang ZJ, Lv ZC, et al. Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review[J]. Front Immunol, 2021, 12: 653437.
|
| 44 |
Sogbe M, López-Guerra D, Blanco-Fernández G, et al. Durvalumab as a successful downstaging therapy for liver transplantation in hepatocellular carcinoma: the importance of a washout period[J]. Transplantation, 2021, 105(12): e398-e400.
|
| 45 |
Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation？[J]. Am J Transplant, 2021, 21(5): 1979-1980.
|
| 46 |
Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient？[J]. Am J Transplant, 2020, 20(3): 879-883.
|
| 47 |
Chen GH, Wang GB, Huang F, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period[J]. Transpl Immunol, 2021, 66: 101386.
|
| 48 |
Gao Q, Anwar IJ, Abraham N, et al. Liver transplantation for hepatocellular carcinoma after downstaging or bridging therapy with immune checkpoint inhibitors[J]. Cancers, 2021, 13(24): 6307.
|
| 49 |
李俊杰，蒋文涛，田大治，等. 肝癌肝移植术中无瘤技术[J/CD]. 实用器官移植电子杂志，2017, 5(4): 266-267.
|
| 50 |
Chan KM, Wang YC, Wu TH, et al. The preference for anterior approach major hepatectomy: experience over 3 decades and a propensity score-matching analysis in right hepatectomy for hepatocellular carcinoma[J]. Medicine (Baltimore), 2015, 94(34): e1385.
|
| 51 |
Liu J, Lo CM, Man K. Role of intrahepatic regional immunity in post-transplant cancer recurrence[J]. Engineering, 2022, 10(3): 57-64.
|
| 52 |
Man K． Recurrent malignancy: are we pushing the envelope？[J]. Liver Transpl, 2017, 23(S1): S81-S84.
|
| 53 |
Man K, Ng KT, Lo CM, et al. Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases-activation of cell invasion and migration pathways[J]. Liver Transpl, 2007, 13(12): 1669-1677.
|
| 54 |
Harris AL. Hypoxia-a key regulatory factor in tumour growth[J]. Nat Rev Cancer, 2002, 2(1): 38-47.
|
| 55 |
Nagai S, Yoshida A, Facciuto M, et al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation[J]. Hepatology, 2015, 61(3): 895-904.
|
| 56 |
Guarrera JV, Henry SD, Samstein B, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series[J]. Am J Transplant, 2010, 10(2): 372-381.
|
| 57 |
Boteon Y, Flores Carvalho MA, Panconesi R, et al. Preventing tumour recurrence after liver transplantation: the role of machine perfusion[J]. Int J Mol Sci, 2020, 21(16): 5791.
|
| 58 |
Dutkowski P, Polak WG, Muiesan P, et al. First comparison of hypothermic oxygenated perfusion versus static cold storage of human donation after cardiac death liver transplants: an international-matched case analysis[J]. Ann Surg, 2015, 262(5): 764-770; discussion 770-771.
|
| 59 |
Mueller M, Kalisvaart M, O'Rourke J, et al. Hypothermic oxygenated liver perfusion (HOPE) prevents tumor recurrence in liver transplantation from donation after circulatory death[J]. Ann Surg, 2020, 272(5): 759-765.
|
| 60 |
Guo Z, Zhao Q, Jia Z, et al. A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease[J]. J Hepatol, 2023.[online ahead of print]
|
| 61 |
Ascha MS, Ascha ML, Hanouneh IA. Management of immunosuppressant agents following liver transplantation: less is more[J]. World J Hepatol, 2016, 8(3): 148-161.
|
| 62 |
Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol, 2013, 59(6): 1193-1199.
|
| 63 |
Lerut J, Iesari S, Foguenne M, et al. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression？[J]. Transl Gastroenterol Hepatol, 2017, 2: 80.
|
| 64 |
Chen K, Man K, Metselaar HJ, et al. Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation[J]. Liver Transpl, 2014, 20(3): 261-269.
|
| 65 |
Wei Q, Gao F, Zhuang R, et al. A national report from China Liver Transplant Registry: steroid avoidance after liver transplantation for hepatocellular carcinoma[J]. Chin J Cancer Res, 2017, 29(5): 426-437.
|
| 66 |
Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma[J]. Gastroenterology, 2008, 135(6): 1972-1983.e11.
|